Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
KQ-2003 / Novatim Immune Therap
NCT04714827: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma	Recruiting	1/2	24	RoW	KQ-2003 CAR-T cells, Fluorine dara marina injection, Cyclophosphamide injection, CD19-BCMA CAR-T Cells	Shanxi Province Cancer Hospital, Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	Multiple Myeloma	09/24	12/25
NCT06223646: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma	Recruiting	1/2	29	RoW	KQ-2003 CAR T-cells	Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	Multiple Myeloma	03/26	03/26
NCT06518876: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome	Not yet recruiting	1	21	RoW	KQ-2003 CAR T-cells	Novatim Immune Therapeutics (Zhejiang) Co., Ltd.	POEMS Syndrome	12/27	12/27